Effective Management of Nasal Vestibule Squamous Cell Carcinoma with Cemiplimab: A Case Report

Ferdinando Costabile; Marianna Donnarumma; Arianna Piscosquito; Concetta Ingenito; Michela Rosaria Iuliucci; Carlo Buonerba; Giuseppe Di Lorenzo; Rossella Di Trolio

doi:10.1159/000531843

Effective Management of Nasal Vestibule Squamous Cell Carcinoma with Cemiplimab: A Case Report

Case Rep Oncol. 2023 Sep 19;16(1):935-938. doi: 10.1159/000531843. eCollection 2023 Jan-Dec.

Authors

Ferdinando Costabile^{1

2}, Marianna Donnarumma³, Arianna Piscosquito¹, Concetta Ingenito¹, Michela Rosaria Iuliucci¹, Carlo Buonerba^{1

2}, Giuseppe Di Lorenzo^{1

2}, Rossella Di Trolio⁴

Affiliations

¹ Oncolgy Unit, "Andrea Tortora" Hospital, ASL Salerno, Pagani, Italy.
² Associazione O.R.A.-Oncology Research Assistance, Somma Vesuviana, Italy.
³ Dermatology Unit, "Andrea Tortora" Hospital, ASL Salerno, Pagani, Italy.
⁴ Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, IRCCS Pascale, Naples, Italy.

Abstract

Nasal vestibule squamous cell carcinoma (SCC) is a rare malignancy with limited treatment options. This case report presents an 83-year-old female with SCC of the nasal vestibule who was ineligible for surgery or radiotherapy due to various factors. The patient was successfully treated with cemiplimab, a systemic anti-PD-1 antibody, resulting in a remarkable tumor reduction without any observed side effects. This is the first reported case of nasal vestibule SCC treated with cemiplimab, highlighting its potential as a promising therapeutic option.

Keywords: Cemiplimab; Immunotherapy; Skin cancer; Squamous cell carcinoma.

Publication types

Case Reports

Grants and funding

This research was partially supported by funding from the EUBEA Agency, Naples, Italy, which provided financial support for the publication fees of this article.